New funds bring Forbion’s assets under management to approximately €7.5 billion amid European biotech headwinds
Quartz’s article “Forbion is closing a €2.3 billion fundraise, its largest ever” covers the €2.3 billion ($2.6 billion) raised across Forbion’s two newest funds, marking the firm’s largest fundraising to date. The article notes that the raise exceeded its target and brings assets under management to approximately €7.5 billion, positioning Forbion as Europe’s largest dedicated life sciences venture capital firm by assets under management. It also highlights the geographic breadth of the investor base, with approximately 60% of the capital coming from Europe and 40% from North America.
Forbion Managing Partner and Co-Founder Sander Slootweg, is featured discussing how the additional capital enables Forbion to identify and support the most promising biotech companies in a market facing a general shortage of funding. Quartz explains that Growth Opportunities Fund IV will target later-stage biopharma companies in Europe and North America, while Ventures Fund VIII will invest in therapeutics-focused biotech companies across earlier stages. Together, the funds are expected to finance around 30 companies and provide substantial new capital at a time when Europe’s share of global life sciences venture investment remains significantly below that of the United States.